Halozyme Therapeutics (NASDAQ:HALO) Releases Quarterly Earnings Results, Misses Expectations By $2.16 EPS

Halozyme Therapeutics (NASDAQ:HALO) posted its quarterly earnings data on Tuesday. The biopharmaceutical company reported ($0.24) EPS for the quarter, missing the consensus estimate of $1.92 by ($2.16), FiscalAI reports. Halozyme Therapeutics had a return on equity of 156.95% and a net margin of 47.91%.The firm had revenue of $451.77 million for the quarter, compared to analysts’ expectations of $446.13 million. During the same quarter last year, the firm posted $1.26 earnings per share. Halozyme Therapeutics’s quarterly revenue was up 51.6% on a year-over-year basis.

Here are the key takeaways from Halozyme Therapeutics’ conference call:

• Halozyme reported a record $1.4 billion in 2025 revenue (up 38%) and $868M in royalty revenue (up 52%), driven mainly by ENHANZE-enabled blockbusters DARZALEX SC, Phesgo and VYVGART Hytrulo.
• The company broadened its subcutaneous delivery portfolio by acquiring Elektrofi’s Hypercon and Surf Bio’s hyperconcentration technologies (IP into the mid‑2040s), positioning Halozyme as a one‑stop shop and targeting ~36 combined commercial/development products by 2028.
• Preclinical data indicate ENHANZE may enable safe subcutaneous delivery of antibody‑drug conjugates with much lower Cmax and similar or higher overall exposure, a finding that could materially expand ENHANZE’s addressable modalities if confirmed clinically.
• Management reiterated strong 2026 guidance (total revenue $1.71–$1.81B; royalty revenue $1.13–$1.17B; non‑GAAP EPS $7.75–$8.25) and highlighted balance‑sheet moves (new convertible notes, repurchases, larger revolver) with a plan to delever below 1x net debt/EBITDA by end‑2026.
• Legal and IP risk remains — an IPR involving Alteogen and an active district‑court infringement case (involving Merck) are ongoing, with discovery permitted, creating potential litigation uncertainty for the company.

Halozyme Therapeutics Trading Up 1.3%

Shares of NASDAQ HALO traded up $1.04 during midday trading on Tuesday, reaching $80.48. 2,101,709 shares of the stock were exchanged, compared to its average volume of 1,978,029. The stock has a market capitalization of $9.46 billion, a P/E ratio of 16.94, a PEG ratio of 0.33 and a beta of 0.97. The company has a debt-to-equity ratio of 1.59, a quick ratio of 1.37 and a current ratio of 1.59. The company has a 50 day simple moving average of $71.55 and a 200 day simple moving average of $70.25. Halozyme Therapeutics has a twelve month low of $47.50 and a twelve month high of $82.22.

Analyst Upgrades and Downgrades

A number of equities research analysts have recently issued reports on HALO shares. Weiss Ratings raised shares of Halozyme Therapeutics from a “hold (c+)” rating to a “buy (b-)” rating in a report on Tuesday, February 10th. JPMorgan Chase & Co. boosted their price target on shares of Halozyme Therapeutics from $63.00 to $65.00 and gave the stock a “neutral” rating in a research report on Monday, October 27th. HC Wainwright reaffirmed a “buy” rating on shares of Halozyme Therapeutics in a research note on Thursday, January 29th. Benchmark reissued a “buy” rating on shares of Halozyme Therapeutics in a research note on Tuesday, February 3rd. Finally, Morgan Stanley dropped their price target on Halozyme Therapeutics from $80.00 to $79.00 and set an “overweight” rating for the company in a research report on Monday, October 20th. Seven investment analysts have rated the stock with a Buy rating, four have given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, Halozyme Therapeutics currently has a consensus rating of “Moderate Buy” and a consensus price target of $77.44.

More Halozyme Therapeutics News

Here are the key news stories impacting Halozyme Therapeutics this week:

• Positive Sentiment: Reported record full‑year 2025 total revenue of $1.397B and reiterated 2026 guidance with strong growth ranges (2026 total revenue $1.71–$1.81B; adjusted EBITDA $1.125–$1.205B; non‑GAAP EPS $7.75–$8.25), which supports revenue visibility and margin expansion expectations. PR Newswire Release
• Positive Sentiment: Fourth‑quarter revenue came in at roughly $452M, up ~52% year‑over‑year and slightly above consensus, underscoring continued strength in the ENHANZE royalties and partner revenue streams. Quiver Quant
• Neutral Sentiment: Street sentiment remains broadly constructive (consensus “Moderate Buy” / median price target ~$84.5) though analyst targets vary widely — a mixed analyst backdrop that can mute extreme moves. Quiver Quant (analyst notes)
• Neutral Sentiment: Educational/momentum coverage and retrospectives (e.g., Zacks, MSN/Benzinga previews) may attract momentum and retail interest but are less likely to move the stock materially versus the company’s fundamentals and guidance. Zacks Momentum Piece
• Negative Sentiment: Reported EPS missed consensus (quarterly EPS reported at a loss versus higher analyst expectations) and the company recorded a larger operating and net loss in the quarter, which triggered near‑term selling pressure after the release. MarketBeat Earnings Summary
• Negative Sentiment: Quiver highlights a significant year‑over‑year rise in operating loss and liabilities, plus heavy insider stock sales (multiple executives sold shares recently), which can concern investors about near‑term dilution or sentiment. Quiver Quant (financials & insider activity)

Insider Buying and Selling

In related news, CEO Helen Torley sold 20,000 shares of the stock in a transaction that occurred on Tuesday, February 3rd. The stock was sold at an average price of $76.12, for a total value of $1,522,400.00. Following the completion of the transaction, the chief executive officer directly owned 708,719 shares in the company, valued at approximately $53,947,690.28. This represents a 2.74% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, Director Bernadette Connaughton sold 2,000 shares of Halozyme Therapeutics stock in a transaction on Monday, January 5th. The shares were sold at an average price of $70.25, for a total value of $140,500.00. Following the completion of the sale, the director owned 40,123 shares in the company, valued at $2,818,640.75. This represents a 4.75% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 49,398 shares of company stock worth $3,650,592 over the last quarter. 2.90% of the stock is currently owned by insiders.

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Larson Financial Group LLC boosted its stake in Halozyme Therapeutics by 3,118.2% during the third quarter. Larson Financial Group LLC now owns 354 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 343 shares during the period. Wexford Capital LP acquired a new position in shares of Halozyme Therapeutics in the 3rd quarter worth approximately $70,000. Employees Retirement System of Texas boosted its position in shares of Halozyme Therapeutics by 64.6% during the 3rd quarter. Employees Retirement System of Texas now owns 1,088 shares of the biopharmaceutical company’s stock worth $80,000 after purchasing an additional 427 shares during the period. UMB Bank n.a. boosted its position in shares of Halozyme Therapeutics by 18.2% during the 4th quarter. UMB Bank n.a. now owns 1,296 shares of the biopharmaceutical company’s stock worth $87,000 after purchasing an additional 200 shares during the period. Finally, Smartleaf Asset Management LLC increased its holdings in Halozyme Therapeutics by 21.9% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,399 shares of the biopharmaceutical company’s stock valued at $95,000 after purchasing an additional 251 shares during the last quarter. Institutional investors and hedge funds own 97.79% of the company’s stock.

About Halozyme Therapeutics

Halozyme Therapeutics, Inc is a biopharmaceutical company headquartered in San Diego, California, that specializes in the development and commercialization of novel drug-delivery technologies. Founded in 1998, Halozyme focuses on enabling subcutaneous administration of biologic therapies through its proprietary platforms. The company’s core mission is to improve patient access and convenience while maintaining efficacy and safety profiles comparable to or better than traditional routes of administration.

The company’s flagship technology, ENHANZE®, is based on recombinant human hyaluronidase PH20 (rHuPH20), an enzyme that transiently degrades hyaluronan in the extracellular matrix.